According to the Financial Times, during its latest funding round negotiations, OpenAI has lowered its proposed valuation target from approximately $1.4 trillion—previously communicated to investors—to $1.25 trillion. Earlier reports indicated a fundraising target of around $30 billion. Against the backdrop of a U.S. equity market sell-off, investors remain hesitant about how to value frontier-model companies: should valuation be based on revenue growth, long-term technological leadership, or the total capital required for future investment, discounted accordingly? 5. U.S. to Further Scrutinize AI Investments in China: Transactions Under $50,000 Exempted The U.S. Department of the Treasury has released a draft rule for new foreign investment security reviews, implementing the 2025 Comprehensive Overseas Investment National Security Act (COINS Act). The proposed rule targets sensitive technology investments in designated countries—including China and Russia—covering artificial intelligence, advanced semiconductors, quantum technologies, supercomputing, hypersonic systems, and newly added biotechnology. The Treasury stated that the draft will impose prohibitions on certain AI-related technology investments, while requiring notifications or imposing bans on other sectors depending on transaction specifics. Exceptions apply to certain publicly traded securities investments and transactions under $50,000. 6. Former OpenAI Science Head Raises $215 Million to Launch AI-Driven Drug Discovery Lab: Leveraging AI and Robotics to Bring Offshored Drug R&D Back to the U.S. Kevin Weil, former Chief Product Officer and Head of AI for Science at OpenAI, has officially launched Warp Sciences and secured $215 million in funding, achieving a post-money valuation of $865 million, led by Lightspeed Venture Partners. The founding team includes Manohar Paluri, former AI executive at Meta and founding member of FAIR; DJ Patil, the U.S. government’s first Chief Data Scientist; and Solomon Reisberg, an expert in medicinal chemistry. OpenAI’s Chief Research Officer Mark Chen and CFO Sarah Friar also invested personally. Warp does not aim to develop novel therapeutics directly; instead, it seeks to establish AI-automated drug discovery laboratories within the United States, initially focusing on lead compound optimization: using AI to design experiments, robots to synthesize and test molecular variants, and real-world experimental data to refine AI models—creating a closed-loop cycle of “AI design → robotic experimentation → data feedback → model improvement.” Its business model centers on providing chemical contract research organization (CRO) services to pharmaceutical companies. Notably, the company explicitly aims to repatriate portions of drug R&D work long outsourced to Chinese firms such as WuXi AppTec. A 2024 industry survey found that 74% of surveyed U.S. biotech companies maintain preclinical or clinical service contracts with Chinese partners. 7. Musk’s Restriction of Starlink Services to Ukraine Sparks European Alarm; Palantir Assures NATO Its AI System Has No “Kill Switch” Louis Mosley, Palantir’s Head of European Operations, assured Reuters that the Maven military AI system currently deployed by NATO contains no “kill switch”—neither Palantir nor the U.S. government can remotely deactivate it.

Former OpenAI Executive Raises $215 Million to Enter the AI Drug Discovery Lab Sector

Warp Sciences announced a $215 million funding round on October 22, 2026, led by Lightspeed Venture Partners, with participation from Premji Invest, IVP, and Mayfield. In a public statement, Kevin Weil labeled this as the company’s Series A round. Yet beyond the headline figure lies a more pressing question: What specific service will this startup deliver to customers first? Warp’s answer is highly concrete: synthesizing compounds required by drug discovery teams. Still, the company draws clear boundaries: clients decide which molecules to pursue and retain full control over their drug programs; Warp maintains no proprietary drug pipeline. Its strategy is to first establish robust experimental services—and only then gradually expand automation capabilities. Warp defines its business as a U.S.-based chemical CRO (Contract Research Organization) (Source: Screenshot of Warp Sciences’ official homepage) From OpenAI to Synthesizing Molecules Weil serves as Warp’s CEO and previously held the roles of Chief Product Officer and Vice President of Science at OpenAI. This time, however, the challenge extends beyond models and software—it encompasses hands-on experimental execution and physical delivery. The company enters the market explicitly as a chemical CRO. The other end of the team connects deeply with drug discovery: Chief Scientific Officer Sol Reisberg formerly led medicinal chemistry efforts at Terremoto Biosciences. Chemistry alone, however, is insufficient—the technical backbone is led by Manohar Paluri, former Meta AI executive and founding member of FAIR; operations are overseen by DJ Patil, the U.S. government’s inaugural Chief Data Scientist. Warp’s four co-founders and their respective roles (Source: Screenshot of the “Team” section on Warp Sciences’ official website) Its first service offering can be understood as iterative refinement around a promising “recipe.” Yet clients need tangible molecules for comparative evaluation—not just theoretical designs. This aligns precisely with lead optimization—synthesizing structural analogs around an existing molecule for further biological assessment. The company spells out operational scope on its website: synthesis at milligram-to-gram scale, typically involving complex molecules requiring 5–15 synthetic steps. This falls squarely within the preclinical small-molecule development domain—not industrial-scale manufacturing, nor claims of having achieved novel drug development milestones. Initial service focus: analog synthesis for lead optimization (Source: Screenshot of Warp Sciences’ services page) U.S.-Based Labs: Can They Compete on Cost with Offshore Providers? Narrowing the scope helps clarify client relationships: research teams submit synthesis requests; Warp executes the chemistry. But the company must first demonstrate consistent, reliable delivery of compounds meeting agreed specifications. How AI models evolve must align tightly with the immediate timelines and needs of clients’ ongoing projects. The company lists speed, domestic collaboration, and learning from experiments as core objectives on its website. Yet for clients, the ultimate value of “smarter” technology must manifest in concrete outcomes.

Warp Sciences raises $215 million to challenge overseas chemistry outsourcing labs

23 hours ago

Warp Sciences secured $215 million to launch an AI-driven US contract research organization competing with overseas providers like WuXi AppTec. The startup will combine synthetic chemists, artificial intelligence, and robots to synthesize experimental drug compounds.

cen

2026-11-03

Warp Sciences raises $215 million to challenge overseas chemistry outsourcing labs

Warp Sciences raises $215 million to challenge overseas chemistry outsourcing labs

FAQ